



# Impedance planimetry during per-oral endoscopic myotomy is associated with decreased inadvertent capnoperitoneum

Matthew F. Mikulski<sup>1,3</sup> · Timothy J. Morley<sup>1</sup> · Kaitlin P. Debbink<sup>1</sup> · David J. Desilets<sup>2</sup> · John R. Romanelli<sup>1</sup>

Received: 12 March 2023 / Accepted: 12 October 2023 / Published online: 21 November 2023  
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023

## Abstract

**Background** Per-oral endoscopic myotomy (POEM) has become an accepted minimally invasive alternative to Heller myotomy for the treatment of achalasia and other disorders of esophageal dysmotility. One associated adverse event is the inadvertent creation of capnoperitoneum. A proposed mechanism is that extension of the submucosal tunnel below the esophageal hiatus and onto the gastric wall leads to transmural perforation. We hypothesized that the use of impedance planimetry with the endoscopic functional luminal imaging probe (EndoFLIP) more accurately identifies the esophagogastric junction and helps to better define the myotomy's ideal limits, thus lowering the incidence of inadvertent capnoperitoneum.

**Methods** This is a single-center, retrospective review of consecutive POEM cases from 06/11/2011 to 08/08/2022, with EndoFLIP introduced in 2017. Patient and procedural characteristics, including the incidence of clinically significant capnoperitoneum and decompression, were analyzed using univariate and multivariable linear regression statistics.

**Results** There were 140 POEM cases identified, 74 (52.9%) of which used EndoFLIP. Clinically significant capnoperitoneum was encountered in 26 (18.6%) cases, with no differences in patient characteristics between those who had capnoperitoneum and those who did not. There was a decreased incidence of capnoperitoneum in cases using EndoFLIP compared to those without ( $n = 6, 23\%$  vs  $n = 20, 77\%$ ,  $p = 0.001$ ), with zero instances in the final 56 cases. After adjusting for potentially confounding factors, EndoFLIP use was associated with a  $-15.93\%$  (95% confidence interval  $-30.68\%$ ,  $-1.18\%$ ) decrease in procedure duration.

**Conclusions** The routine use of EndoFLIP during POEM was associated with decreased incidence of clinically significant capnoperitoneum, potentially due to improved myotomy tailoring and decreased duration of insufflation with shorter procedure times.


---

**Previous presentation** Data from this work was originally presented at the Society of American Gastrointestinal and Endoscopic Surgeons 2022 Annual Meeting, Denver, CO, USA, March 2022.

---

Extended author information available on the last page of the article

## Graphical abstract



**Keywords** Per-oral endoscopic myotomy · Impedance planimetry · Capnoperitoneum

### Abbreviations

AE	Adverse events
CI	Confidence interval
EGJ	Esophagogastric junction
EndoFLIP	Endoluminal functional luminal imaging probe
IQR	Interquartile range
NAEDD	Non-achalasia esophageal dysmotility disorders
POEM	Per-oral endoscopic myotomy

Achalasia is a neuromuscular disease of the esophagus characterized by elevated lower esophageal sphincter pressures with a lack of peristalsis. This induces intolerance to solid meals and eventually progresses to intolerance to liquids, including secretions. It has an incidence of 1.6 in 100,000 people, and a prevalence of 10.8 in 100,000, which has risen sharply in recent years [1]. Other non-achalasia esophageal dysmotility disorders (NAEDD) can present similarly to achalasia, despite different pathophysiologies. According to the Chicago Classification Version 4.0, NAEDD includes esophagogastric junction (EGJ) outflow obstruction, distal esophageal spasm, hypercontractile esophagus, and other minor disorders of peristalsis (formerly known as nutcracker esophagus in Chicago Classification version 3.0) [2–4].

Treatment for both achalasia and NAEDD has consisted of medical management with nitrates and calcium channel blockers, endoscopic interventions including injection of botulinum toxin and pneumatic dilation, and surgical management with laparoscopic or thoracoscopic Heller myotomy

[5, 6]. Per-oral endoscopic myotomy (POEM) has gained traction as a less invasive alternative to Heller myotomy with fundoplication in the treatment of achalasia and, increasingly, has been employed in treating NAEDD [7–11]. POEM consists of an endoscopic mucosal incision and creation of a submucosal tunnel before performing an endoscopic myotomy and closure of the mucosal incision, although the ideal length of the gastric myotomy remains up for debate [7, 12]. Multiple case series and retrospective reviews have proven its safety and efficacy and show decreased postprocedural hospital stay and recovery time [13–17]. One potential disadvantage to the per-oral endoscopic technique is the difficulty understanding extraluminal anatomy and knowing where in the esophagus the dissection is taking place. This can cause dissection to proceed beyond the diaphragmatic hiatus onto the gastric wall. Therefore, a widely reported adverse event associated with POEM is the inadvertent creation of capnoperitoneum during the myotomy [18–20]. When clinically significant, this can be successfully treated with needle decompression without long-term sequelae, particularly when carbon dioxide insufflation is preferentially used over room air [20]. The exact underlying mechanism has not been clearly defined, but it may be that when the submucosal tunnel is extended below the esophageal hiatus and onto the gastric wall (with potential differences in angle or length of the gastric myotomy), transmural perforation can occur. Although the esophagus does not have a serosal layer, adherent mediastinal tissues prevent gross capnoperitoneum when this space is entered and can serve the same function that the serosa does in other parts of the gastrointestinal tract [21].

Previously, many surgeons relied on anatomic measurements using the endoscope to delineate the myotomy's length and location; this can be notoriously unreliable as the endoscope is nonlinear and the scope can bow in the submucosal tunnel. The endoluminal functional luminal imaging probe (EndoFLIP; Medtronic, Dublin, Ireland) is an endoscopic device that utilizes a catheter-directed balloon to measure impedance planimetry and thereby assess cross-sectional area, maximum diameter, and distensibility index of the lumen (i.e., cross-sectional area of the EGJ divided by the intra-balloon pressure at that time) in real time [22]. While submucosal anatomy is traditionally used to identify the EGJ, such as identification of palisade vessels or tunnel narrowing, EndoFLIP more accurately identifies the anatomic location of the EGJ and allows for the tailoring of the myotomy to the most directed area [23]. It has emerged as a useful adjunct to guide myotomy creation, and several studies have demonstrated its utility and safety [22, 24–26].

At our institution, we have performed over 140 cases of POEM for achalasia and other NAEDD and have adopted routine use of EndoFLIP to guide myotomy limits. We present a retrospective case series of patients who have undergone POEM and report the incidence of capnoperitoneum before and after the adoption of EndoFLIP. We hypothesized that the use of EndoFLIP, with its ability to more accurately identify the EGJ and define the myotomy's ideal limits, would lower the incidence of inadvertent clinically significant capnoperitoneum.

## Materials and methods

Approval for this study was obtained by the Institutional Review Board of the University of Massachusetts Chan Medical School at Baystate Medical Center. This is a single-center retrospective review of consecutive POEM cases of patients  $\geq 18$  years old from June 10, 2011, to August 8, 2022. Exclusion criteria included any POEM cases that were converted to Heller myotomy in the same case. All patients underwent preprocedural high-resolution manometry. Patients were divided into two groups based on the indication for the procedure, achalasia, or NAEDD, with NAEDD cases initially characterized according to the Third Edition of the Chicago Classification [4] and were reviewed and reclassified according to the Fourth Edition [2, 3] when applicable.

## Procedure

POEM was performed by a single surgeon-endoscopist team under general anesthesia. Full details of the procedure from our institution have been previously described [11, 21]. In brief, after induction of general anesthesia, a standard

gastroscope is inserted orally and the EGJ is identified. A submucosal cushion is created with saline and methylene blue dye and the mucosa is opened with monopolar cautery. Dissection is carried to the level of the visualized circular muscle fibers, extended distally to the level of the EGJ, and then extended beyond it 2 cm onto the stomach. A retroflexed view of the stomach is obtained. Dye from the submucosal tunnel is often visualized extending onto the stomach confirming adequate distal dissection. The tunnel is re-entered and the myotomy is performed. Gentamicin 80 mg in 60 cc saline is injected through the endoscope into the tunnel to help prevent bacterial contamination from oral flora in the closed space of the tunnel, and the mucosal incision is closed.

An EndoFLIP 1.0 unit and an 8 cm catheter (EF-325) were used during this study period using the methods described at other centers [27]. Regardless of preprocedural diagnosis, the catheter is zeroed to atmospheric pressure after completing the pre-check and purge process. Once the patient is intubated, the EndoFLIP catheter is advanced under endoscopic guidance into the stomach. The scope is then removed and the balloon is filled to 30 mL, then slowly withdrawn until an hourglass shape is seen on the monitor. After allowing the readings to stabilize, minimum diameter, cross-sectional area, intra-bag pressure, and distensibility index are recorded. The narrowest aspect of the hourglass has the tightest diameter and indicates the highest pressure zone, accurately depicting the lower esophageal sphincter. The balloon is subsequently deflated and the catheter is removed. Following myotomy, the catheter is again inserted under endoscopic guidance to prevent intubation of the submucosal tunnel, and the measurements are repeated.

Since radiographic capnoperitoneum after POEM is very frequent, capnoperitoneum is defined as *clinically significant* if abdominal distention is visible to the naked eye and the abdomen is tense and firm, akin to capnoperitoneum created during laparoscopy. When encountered, Veress needle decompression in the left upper quadrant of the abdomen is performed at the end of the case, allowing the abdomen to decompress until visible collapse of the abdominal wall is seen.

Procedure time is defined as the duration of time between mucosal opening until the endoscope is withdrawn at the end of the case—thus anesthesia-related operating room time, initial diagnostic esophagogastroduodenoscopy, first EndoFLIP measurement when implemented, and Veress needle decompression when performed are not counted in this measure.

## Statistical analyses

Numeric values are represented as  $n$  (%). Continuous variables with normal distribution are presented as

mean  $\pm$  standard deviation (SD) and non-normal distributions are presented as median [interquartile range (IQR)]. Pearson's  $\chi^2$  test was utilized for categorical comparisons, unpaired t-test was used for continuous variables with normal distribution, and Wilcoxon signed-rank test was utilized for continuous, non-normally distributed comparisons. Multivariable linear regression was utilized to analyze the procedure time of POEM while adjusting for potentially confounding factors. Factors considered clinically relevant were included in the model. As part of the model, the first 40 POEM cases in the series were designated as part of a "learning curve" in the initial adoption of POEM. This number was decided with the opinion and experience of the surgeon-endoscopist team along with support from three high-volume studies in which 25–40 cases were required by experienced endoscopists to achieve technical efficiency in POEM, which we erred on the conservative side of these reports [28–30]. All variables in the model were assessed for collinearity. All tests were two-tailed and  $p < 0.05$  was considered significant. Statistical analyses were performed using R [31].

## Results

### Patient population and baseline characteristics

There were 143 patients who underwent POEM. Three patients were excluded from analysis: one procedure was aborted intraoperatively prior to POEM completion for tension capnopericardium resulting in cardiac arrest [32], one was aborted in a patient with prior laparoscopic Heller myotomy because the team was unable to safely create the submucosal tunnel sufficiently to reach the EGJ and perform the myotomy, and the third was converted intraoperatively to a Heller myotomy (it was later discovered that the patient had Botox administration 1 week prior at an outside institution without disclosing this information). This left 140 cases in final analysis. Patients were mean  $57 \pm 16.5$  years old at POEM, 77 (55%) were female, and median body mass index was 29 [IQR 23.3–34.4]. POEM was most commonly performed for achalasia ( $n = 119$ , 85%). Patient histories prior to POEM included 9 (6%) who had previously undergone Botox injection, 45 (32%) had previously undergone endoscopic dilation, and 9 (6%) had previous Heller myotomy.

### EndoFLIP characteristics

EndoFLIP was utilized starting in 2017 and has been used on all cases since 2018 for a total of 74 (53%) cases. Characteristics of patients who underwent EndoFLIP and those who did not are depicted in Table 1. EndoFLIP patients were associated with increased frequency of NAEDD

diagnosis ( $n = 17$ , 23% vs.  $n = 4$ , 6%,  $p = 0.005$ ) and had fewer instances of pre-POEM esophageal dilation ( $n = 17$ , 23% vs.  $n = 28$ , 42%,  $p = 0.014$ ) than no EndoFLIP. EndoFLIP was additionally associated with shorter median overall myotomy lengths (12 [IQR 11–13] vs 13 [IQR 12–15] cm,  $p = 0.002$ ) and gastric myotomy lengths (2 [IQR 2–2] vs. 2 [IQR 2–3] cm,  $p < 0.001$ ) compared to no EndoFLIP.

### Clinically significant capnoperitoneum

Capnoperitoneum was encountered in 26 (18.6%) cases (Table 2). No cases caused hemodynamic instability and all were decompressed with Veress needle intraoperatively without significant immediate or delayed adverse effects. Cases of capnoperitoneum correlated with volume per year from 2011 to 2018 (Fig. 1a). Percent incidence of capnoperitoneum declined over time, with no cases encountered from 2019 to 2022 (Fig. 1b). There were no differences between patients that developed capnoperitoneum and those that did not in terms of demographics, preprocedural diagnosis or interventions, or pre- or postprocedural Eckardt scores (Tables 1 and 2). EndoFLIP was associated with a lower incidence of capnoperitoneum compared to those without EndoFLIP use ( $n = 6$ , 23% vs  $n = 20$ , 77%,  $p = 0.001$ ) and the median gastric myotomy length was longer in patients who developed capnoperitoneum compared to those who did not (2 [IQR 2–3] cm vs. 2 [IQR 2–2] cm,  $p = 0.023$ ). Patients who had capnoperitoneum additionally had slightly longer post-POEM length of stay compared to those without capnoperitoneum (median 1 [IQR 1–2] vs. 1 [IQR 1–1] days,  $p = 0.028$ ).

### Procedure time

Procedure time declined steadily throughout the early part of the study with subsequent trend toward increasing procedure time in the latest years, likely due to increased participation from gastrointestinal and surgical fellows (Fig. 2). Median procedure time was shorter in patients where EndoFLIP was used compared to those in whom it was not (97 [IQR 82.3–119.5] vs. 133 [IQR 107–155],  $p < 0.001$ ). Additionally, median procedure time was longer in patients that developed capnoperitoneum compared to those that did not (136.5 [IQR 103–158.2] vs. 110 [IQR 86–136] min,  $p = 0.009$ ).

After identifying that capnoperitoneum cases and EndoFLIP cases were each longer in duration, thereby having increased duration of insufflation, a multivariable linear regression was performed to determine if procedure duration was independently associated with these factors (Table 3). After adjustment, historical manipulations such as Botox, endoscopic dilation, or Heller myotomy, learning curve cases, and clinically significant capnoperitoneum

**Table 1** Baseline characteristics of patients stratified by use of EndoFLIP

Factor	Total <i>n</i> = 140	EndoFLIP <i>n</i> = 74	No EndoFLIP <i>n</i> = 66	<i>p</i> value
<b>Demographics</b>				
Mean age (years) ± SD	57 ± 16.5	58.9 ± 16.7	55 ± 16.2	0.166
Female <i>n</i> (%)	77 (55%)	36 (49%)	41 (62%)	0.110
Median body mass index [IQR]	29 [23.3–34.4]	26.7 [23.8–34.8]	27.6 [22.4–34.3]	0.767
<b>Diagnosis</b>				
Achalasia <i>n</i> (%)	119 (85%)	57 (77%)	62 (94%)	<b>0.005</b>
NAEDD <i>n</i> (%)	21 (15%)	17 (23%)	4 (6%)	
<b>Pre-POEM intervention</b>				
Botox <i>n</i> (%)	9 (6%)	2 (3%)	7 (11%)	0.057
Esophageal dilation <i>n</i> (%)	45 (32%)	17 (23%)	28 (42%)	<b>0.014</b>
Laparoscopic Heller myotomy <i>n</i> (%)	9 (6%)	3 (4%)	6 (9%)	0.225
<b>Median Eckardt score</b>				
Pre-POEM [IQR]	7 [6–9]	7 [5.5–9]	7.5 [6–9]	0.432
Post-POEM [IQR]	0 [0–0]	0 [0–0]	0 [0–1]	0.118
<b>Procedural characteristics</b>				
Median procedure duration (min) [IQR]	115 [88–141.5]	97 [82.3–119.5]	133 [107–155]	<b>&lt; 0.001</b>
<b>Myotomy approach</b>				
Anterior <i>n</i> (%)	126 (90%)	70 (95%)	56 (85%)	0.055
Posterior or lateral <i>n</i> (%)	14 (10%)	4 (5%)	10 (15%)	
Median esophagogastric junction location (cm) [IQR]	40 [39–42.3]	40.5 [39–42]	40 [39.3–43]	0.853
Median total myotomy length (cm) [IQR]	12 [12–14]	12 [11–13]	13 [12–15]	<b>0.002</b>
Median gastric myotomy length (cm) [IQR]	2 [2–2]	2 [2–2]	2 [2–3]	<b>&lt; 0.001</b>
Median length of stay (days) [IQR]	1 [1–1]	1 [1–1]	1 [1–1]	0.051

Bold values denote the statistical significance

*IQR* interquartile range, *NAEDD* non-achalasia esophageal dysmotility disorder, *POEM* per-oral endoscopic myotomy

creation were not associated with procedure times. Patients with an achalasia diagnoses were associated with an 18.65% (95% CI 2.99%, 34.32%,  $p = 0.021$ ) longer procedure time. Factors associated with decreased procedure times included female sex (– 12.93% (95% CI – 24.9%, – 0.96%,  $p = 0.036$ ) decrease) and use of EndoFLIP (– 15.93% (95% CI – 30.68%, – 1.18%,  $p = 0.036$ ) decrease).

### Subgroup analysis of immediately before and after adoption of EndoFLIP

Because capnoperitoneum and procedural time differences might be a product of the learning curve in the adoption of POEM in general and not attributed to EndoFLIP, a subgroup analysis of the twenty procedures immediately preceding and following the adoption of EndoFLIP was performed (Table 4). These cases were all beyond the first 40 cases of POEM in the series. This analysis found the first 20 EndoFLIP cases were in older patients ( $61.9 \pm 13.3$  vs.  $51.8 \pm 13.5$ ,  $p = 0.04$ ) compared to the preceding 20 cases without EndoFLIP, as well as EndoFLIP being associated with decreased procedural times (median 91 [IQR

81–104.5] vs 125.5 [IQR 104.2–141] min,  $p = 0.004$ ) compared to no EndoFLIP. Of note, there was no difference in the rate of capnoperitoneum between these groups. There were no other associations among underlying diagnosis, pre-POEM interventions, Eckardt scores, or procedural characteristics including overall and gastric myotomy lengths.

### Discussion

This study, to the authors' knowledge, is the first to investigate the use of EndoFLIP and its association with clinically significant capnoperitoneum during POEM. We found capnoperitoneum to be a fairly common occurrence with an incidence of 18.6% in our series. We additionally found a decreased incidence of capnoperitoneum, potentially due to shorter gastric myotomy lengths and ~ 16% shorter procedure times leading to decreased insufflation through the routine adoption of EndoFLIP during POEM.

**Table 2** Patient characteristics and univariate analysis of clinically significant capnoperitoneum

Factor	Total <i>n</i> = 140	Capnoperitoneum <i>n</i> = 26	No capnoperitoneum <i>n</i> = 114	<i>p</i> value
<b>Demographics</b>				
Mean age (years) ± SD	57 ± 16.5	61.7 ± 14	56 ± 17	0.08
Female <i>n</i> (%)	77 (55%)	18 (69%)	59 (52%)	0.106
Median body mass index [IQR]	29 [23.3–34.4]	26.3 [21.9–34.2]	29.8 [23.6–34.5]	0.413
<b>Diagnosis</b>				
Achalasia <i>n</i> (%)	119 (85%)	23 (89%)	96 (84%)	0.584
NAEDD <i>n</i> (%)	21 (15%)	3 (12%)	18 (16%)	
<b>Pre-POEM intervention</b>				
Botox <i>n</i> (%)	9 (6%)	2 (8%)	7 (6%)	0.771
Esophageal dilation <i>n</i> (%)	45 (32%)	11 (42%)	34 (30%)	0.219
Laparoscopic Heller myotomy <i>n</i> (%)	9 (6%)	1 (4%)	8 (7%)	0.552
<b>Median Eckardt score</b>				
Pre-POEM [IQR]	7 [6–9]	8 [6–8.3]	7 [6–9]	0.984
Post-POEM [IQR]	0 [0–0]	0 [0–1.5]	0 [0–0]	0.259
<b>Procedural characteristics</b>				
Median procedure duration (min) [IQR]	115 [88–141.5]	136.5 [103–158.2]	110 [86–136]	<b>0.009</b>
<b>Myotomy approach</b>				
Anterior <i>n</i> (%)	126 (90%)	24 (92%)	102 (90%)	0.664
Posterior or lateral <i>n</i> (%)	14 (10%)	2 (8%)	12 (11%)	
Median esophagogastric junction location (cm) [IQR]	40 [39–42.3]	40 [40–42]	40 [39–42.8]	0.974
Median total myotomy length (cm) [IQR]	12 [12–14]	12 [11–15]	12 [12–13]	0.876
Median gastric myotomy length (cm) [IQR]	2 [2–2]	2 [2–3]	2 [2–2]	<b>0.023</b>
EndoFLIP used <i>n</i> (%)	74 (53%)	6 (23%)	68 (60%)	<b>0.001</b>
Length of stay (days) [IQR]	1 [1–1]	1 [1–2]	1 [1–1]	<b>0.028</b>

Bold values denote the statistical significance

*IQR* interquartile range, *NAEDD* non-achalasia esophageal dysmotility disorder, *POEM* per-oral endoscopic myotomy

### Clinically significant capnoperitoneum


As the adoption of POEM broadens to non-achalasia diagnoses and to cases of higher complexity, the potential for adverse events remains high [8–11, 30, 32–35]. Capnoperitoneum during POEM has the potential to cause severe complications, especially in those patients who cannot tolerate the physiologic consequences associated with capnoperitoneum. Additionally, the treatment of clinically significant capnoperitoneum requires decompression through Veress needle insertion, which introduces risks inherent to abdominal wall penetration such as violation of abdominal viscera, even if that adverse event was not encountered in this series. This becomes more poignant if POEM is performed in an endoscopy suite and potentially without a provider trained in surgical decompression of the abdomen. This study found that the utilization of EndoFLIP, potentially secondary to more precise tailoring and shortening of the overall and gastric myotomies and decreased duration of insufflation through shorter procedure times, was associated with a decreased incidence of clinically significant capnoperitoneum, and this

adverse event was not found in the last 3.5 years of the study after the adoption of EndoFLIP.

Our interpretation of “clinically significant” capnoperitoneum should be viewed in the light that there were no objective measures employed other than gross visualization and feel of the abdomen, which may differ depending on a patient’s body habitus. Additionally, no patients had hemodynamic instability secondary to the capnoperitoneum, but this would not be expected, akin to laparoscopy insufflation. However, capnoperitoneum causing visible abdominal distention that goes beyond slight radiographic capnoperitoneum is substantially uncomfortable and could lead to increased postprocedural pain medications, can increase patient anxiety, and could take time to dissipate, prolonging hospital stays, and therefore, it is still clinically meaningful even if not a high-morbidity occurrence.

Importantly, historical factors such as Botox injection, esophageal dilation, or Heller myotomy, or periprocedural factors such as myotomy approach and overall myotomy length, were not associated with the development of capnoperitoneum. These suggest that complexity of the case and

**Fig. 1** **a** Displays the distribution of POEM cases and incidence of clinically significant capnoperitoneum over time. **b** Displays the percent incidence of clinically significant capnoperitoneum over time




fibrosis from previous manipulation were not risks for capnoperitoneum development. It should be reiterated that the ideal overall and gastric myotomy lengths have not yet been established for POEM, but EndoFLIP was associated with shorter overall and gastric myotomy lengths in our series without any impact on post-POEM Eckardt scores. Additionally, while there are multiple methods of determining the EGJ location, such as placement of clips with fluoroscopy, double endoscopy, and indocyanine green injection, some are fairly resource-intensive or newer techniques. EndoFLIP, however, is a relatively established method and suits mid-size regional programs such as ours [36].

It is important to note that, in our region, the use of Botox and dilation to treat achalasia prior to POEM has fallen substantially in part due to the widespread

acceptance of POEM, which was reflected in the lower proportion of EndoFLIP patients having undergone previous endoscopic esophageal dilation. Thus, later cases in the series may have had less difficult dissections and the chances of inadvertent capnoperitoneum might be reduced. The authors acknowledge that the declining rate of capnoperitoneum even before the routine use of EndoFLIP could represent the learning curve in POEM—as it has been reported that up to 100 cases are required to achieve proficiency [37] in contrast to the 25–40 reported in other studies [17, 28, 30]. However, the 56 consecutive cases without clinically significant capnoperitoneum from 2019 to 2022 after adoption of EndoFLIP remains an important designation.

**Fig. 2** Box-and-whisker plot of procedure time per year. *Key* box (bottom to top)= quartile 1, median, quartile 3; whiskers (bottom to top)= minimum, maximum; dot = significant outlier



**Table 3** Multivariable linear regression of POEM procedure duration

Factor	Percent change	95% confidence interval	<i>p</i> value
<b>Patient characteristics</b>			
Age (per year increase)	0.08%	(− 0.25%, 0.41%)	0.649
Female	− 12.93%	(− 24.9%, − 0.96%)	<b>0.036</b>
Body mass index	0.35%	(− 0.31%, 1%)	0.302
Achalasia diagnosis	18.65%	(2.99%, 34.32%)	<b>0.021</b>
<b>Historical considerations</b>			
Pre-POEM Botox	− 3.79%	(− 25.05%, 17.47%)	0.727
Pre-POEM endoscopic dilation	3.29%	(− 8.8%, 15.38%)	0.595
Pre-POEM Heller myotomy	14.13%	(− 15.28%, 43.55%)	0.348
Learning curve (first 40 cases)	14.87%	(− 0.2%, 29.93%)	0.056
<b>Procedural considerations</b>			
Esophagogastric junction location (per cm increase)	− 0.37%	(− 2.19%, 1.44%)	0.687
Anterior myotomy approach	3.44%	(− 19.34%, 26.23%)	0.768
Length of myotomy (per cm increase)	1.23%	(− 0.98%, 3.43%)	0.277
Capnoperitoneum encountered	9.93%	(− 3.61%, 23.48%)	0.153
EndoFLIP use	− 15.93%	(− 30.68%, − 1.18%)	<b>0.036</b>

Bold values denote statistical significance

POEM per-oral endoscopic myotomy

## Limitations

We present a retrospective series by a single surgeon-endoscopist team, potentially limiting its generalizability. While clinically significant capnoperitoneum was evacuated in all cases in this series when encountered, it is unclear if this is a necessary step in all cases. The prevalence of capnoperitoneum in this series was not sufficient to perform multivariable analysis to find independent

associations with capnoperitoneum creation and thus our associations with shorter gastric myotomy lengths and decreased procedure times will need further verification. Lastly, it was not documented if cases had resident or fellow participation, and to what degree; therefore, the procedure times might be skewed, but the consistency of the surgeon-endoscopist team and performance of the procedure consistently at this tertiary teaching hospital mitigate some of these concerns.



**Table 4** Subgroup analysis of first twenty cases of before and after the adoption of EndoFLIP

Factor	Total <i>n</i> = 40	EndoFLIP <i>n</i> = 20	No EndoFLIP <i>n</i> = 20	<i>p</i> value
<b>Demographics</b>				
Mean age (years) ± SD	56.8 ± 14.2	61.9 ± 13.3	51.8 ± 13.5	<b>0.04</b>
Female <i>n</i> (%)	26 (65%)	13 (65%)	13 (65%)	> 0.999
Median body mass index [IQR]	29.7 [25.4–34.3]	30 [27–36.9]	28.2 [24.5–33.4]	0.399
<b>Diagnosis</b>				
Achalasia <i>n</i> (%)	31 (%)	13 (65%)	18 (90%)	0.058
NAEDD <i>n</i> (%)	9 (%)	7 (35%)	2 (10%)	
<b>Pre-POEM intervention</b>				
Botox <i>n</i> (%)	2 (5%)	1 (5%)	1 (5%)	–
Esophageal dilation <i>n</i> (%)	12 (30%)	6 (%)	6 (30%)	> 0.999
Laparoscopic Heller myotomy <i>n</i> (%)	1 (3%)	0 (0%)	1 (5%)	–
<b>Median Eckardt score</b>				
Pre-POEM [IQR]	7 [6–8]	7 [5.5–8]	6 [6–8]	0.745
Post-POEM [IQR]	0 [0–1]	0 [0–1]	0 [0–1]	0.796
<b>Procedural characteristics</b>				
Median procedure duration (min) [IQR]	104.5 [83.5–128]	91 [81–104.5]	125.5 [104.2–141]	<b>0.004</b>
<b>Myotomy approach</b>				
Anterior <i>n</i> (%)	36 (90%)	19 (95%)	17 (85%)	0.292
Posterior or lateral <i>n</i> (%)	4 (10%)	1 (5%)	3 (15%)	
Median esophagogastric junction location (cm) [IQR]	40 [39–42]	40.5 [38.8–42]	40 [39–43]	0.622
Median total myotomy length (cm) [IQR]	12.5 [11.8–15.3]	12 [10–14.8]	13 [12–15.3]	0.185
Median gastric myotomy length (cm) [IQR]	2 [2–2]	2 [2–2]	2 [2–2]	0.654
Capnoperitoneum encountered	10 (25%)	6 (30%)	4 (20%)	0.465
Median length of stay (days) [IQR]	1 [1–1]	1 [1–1]	1 [1–2]	0.084

## Conclusion

The routine use of EndoFLIP during POEM is associated with a decrease in clinically significant capnoperitoneum, potentially secondary to more tailored and accurate esophageal and gastric myotomy and decreased procedure times leading to decreased duration of insufflation.

**Acknowledgements** None.

**Funding** None.

## Declarations

**Disclosures** John R. Romanelli receives research funding from Davol and consulting fees from New View Surgical. Matthew F. Mikulski, Timothy J. Morley, Kaitlin P. Debbink, and David J. Desilets have no conflict of interest.

## References

- Sadowski DC, Ackah F, Jiang B, Svenson LW (2010) Achalasia: incidence, prevalence and survival. A population-based study. *Neurogastroenterol Motil* 22:e256–e261. <https://doi.org/10.1111/j.1365-2982.2010.01511.x>
- Yadlapati R, Kahrilas PJ, Fox MR, Bredenoord AJ, Prakash Gyawali C, Roman S, Babaei A, Mittal RK, Rommel N, Savarino E, Sifrim D, Smout A, Vaezi MF, Zerbib F, Akiyama J, Bhatia S, Bor S, Carlson DA, Chen JW, Cisternas D, Cock C, Coss-Adame E, de Bortoli N, Defilippi C, Fass R, Ghoshal UC, Gonlachanvit S, Hani A, Hebbard GS, Wook Jung K, Katz P, Katzka DA, Khan A, Kohn GP, Lazarescu A, Lenglinger J, Mittal SK, Omari T, Park MI, Penagini R, Pohl D, Richter JE, Serra J, Sweis R, Tack J, Tatum RP, Tutuian R, Vela MF, Wong RK, Wu JC, Xiao Y, Pandolfino JE (2021) Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0©. *Neurogastroenterol Motil* 33:e14058. <https://doi.org/10.1111/nmo.14058>
- Bredenoord AJ, Fox M, Kahrilas PJ, Pandolfino JE, Schwizer W, Smout AJPM; International High Resolution Manometry Working Group (2012) Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography. *Neurogastroenterol Motil* 24(Suppl 1):57–65. <https://doi.org/10.1111/j.1365-2982.2011.01834.x>
- Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, Roman S, Smout AJPM, Pandolfino JE; International High Resolution Manometry Working Group (2015) The Chicago classification of esophageal motility disorders, v3.0. *Neurogastroenterol Motil* 27:160–174. <https://doi.org/10.1111/nmo.12477>
- Eckardt AJ, Eckardt VF (2011) Treatment and surveillance strategies in achalasia: an update. *Nat Rev Gastroenterol Hepatol* 8:311–319. <https://doi.org/10.1038/nrgastro.2011.68>

6. Ehlers AP, Oelschlagel BK, Pellegrini CA, Wright AS, Saunders MD, Flum DR, He H, Farjah F (2017) Achalasia treatment, outcomes, utilization, and costs: a population-based study from the United States. *J Am Coll Surg* 225:380–386. <https://doi.org/10.1016/j.jamcollsurg.2017.05.014>
7. Inoue H, Minami H, Kobayashi Y, Sato Y, Kaga M, Suzuki M, Satodate H, Odaka N, Itoh H, Kudo S (2010) Peroral endoscopic myotomy (POEM) for esophageal achalasia. *Endoscopy* 42:265–271. <https://doi.org/10.1055/s-0029-1244080>
8. Filicori F, Dunst CM, Sharata A, Abdelmoaty WF, Zihni AM, Reavis KM, Demeester SR, Swanström LL (2019) Long-term outcomes following POEM for non-achalasia motility disorders of the esophagus. *Surg Endosc* 33:1632–1639. <https://doi.org/10.1007/s00464-018-6438-z>
9. Bernardot L, Roman S, Barret M, Vitton V, Wallenhorst T, Pioche M, Chaussade S, Gonzalez J-M, Ponchon T, Prat F, Barthet M, Vergniol J, Chabrun E, Zerbib F (2020) Efficacy of per-oral endoscopic myotomy for the treatment of non-achalasia esophageal motor disorders. *Surg Endosc* 34:5508–5515. <https://doi.org/10.1007/s00464-019-07348-y>
10. Khashab MA, Familiari P, Draganov PV, Aridi HD, Cho JY, Ujiki M, Rio Tinto R, Louis H, Desai PN, Velanovich V, Albéniz E, Haji A, Marks J, Costamagna G, Devière J, Perbtani Y, Hedberg M, Estremera F, Martin Del Campo LA, Yang D, Bukhari M, Brewer O, Sanaei O, Fayad L, Agarwal A, Kumbhari V, Chen Y-I (2018) Peroral endoscopic myotomy is effective and safe in non-achalasia esophageal motility disorders: an international multicenter study. *Endosc Int Open* 6:E1031–E1036. <https://doi.org/10.1055/a-0625-6288>
11. Morley TJ, Mikulski MF, Rade M, Chalhoub J, Desilets DJ, Romanelli JR (2022) Per-oral endoscopic myotomy for the treatment of non-achalasia esophageal dysmotility disorders: experience from a single high-volume center. *Surg Endosc*. <https://doi.org/10.1007/s00464-022-09596-x>
12. Ramirez M, Zubieta C, Ciotola F, Amenabar A, Badaloni A, Nachman F, Nieponice A (2018) Per oral endoscopic myotomy vs. laparoscopic Heller myotomy, does gastric extension length matter? *Surg Endosc* 32:282–288. <https://doi.org/10.1007/s00464-017-5675-x>
13. Inoue H, Sato H, Ikeda H, Onimaru M, Sato C, Minami H, Yokomichi H, Kobayashi Y, Grimes KL, Kudo S (2015) Per-oral endoscopic myotomy: a series of 500 patients. *J Am Coll Surg* 221:256–264. <https://doi.org/10.1016/j.jamcollsurg.2015.03.057>
14. Park CH, Jung DH, Kim DH, Lim C-H, Moon HS, Park JH, Jung H-K, Hong SJ, Choi SC, Lee OY, Achalasia Research Group of the Korean Society of Neurogastroenterology and Motility (2019) Comparative efficacy of per-oral endoscopic myotomy and Heller myotomy in patients with achalasia: a meta-analysis. *Gastrointest Endosc* 90:546–558.e3. <https://doi.org/10.1016/j.gie.2019.05.046>
15. Sanaka MR, Hayat U, Thota PN, Jegadeesan R, Ray M, Gabbard SL, Wadhwa N, Lopez R, Baker ME, Murthy S, Raja S (2016) Efficacy of peroral endoscopic myotomy vs other achalasia treatments in improving esophageal function. *World J Gastroenterol* 22:4918–4925. <https://doi.org/10.3748/wjg.v22.i20.4918>
16. American Society for Gastrointestinal Endoscopy PIVI Committee, Chandrasekhara V, Desilets D, Falk GW, Inoue H, Romanelli JR, Savides TJ, Stavropoulos SN, Swanstrom LL (2015) The American Society for Gastrointestinal Endoscopy PIVI (preservation and incorporation of valuable endoscopic innovations) on peroral endoscopic myotomy. *Gastrointest Endosc* 81:1087–1100.e1. <https://doi.org/10.1016/j.gie.2014.12.007>
17. Patel K, Abbassi-Ghadi N, Markar S, Kumar S, Jethwa P, Zaninotto G (2016) Peroral endoscopic myotomy for the treatment of esophageal achalasia: systematic review and pooled analysis. *Dis Esophagus* 29:807–819. <https://doi.org/10.1111/dote.12387>
18. Werner YB, von Renteln D, Noder T, Schachschal G, Denzer UW, Groth S, Nast JF, Kersten JF, Petzoldt M, Adam G, Mann O, Repici A, Hassan C, Rösch T (2017) Early adverse events of per-oral endoscopic myotomy. *Gastrointest Endosc* 85:708–718.e2. <https://doi.org/10.1016/j.gie.2016.08.033>
19. Nabi Z, Reddy DN, Ramchandani M (2018) Adverse events during and after per-oral endoscopic myotomy: prevention, diagnosis, and management. *Gastrointest Endosc* 87:4–17. <https://doi.org/10.1016/j.gie.2017.09.029>
20. Barbieri LA, Hassan C, Rosati R, Romario UF, Correale L, Repici A (2015) Systematic review and meta-analysis: efficacy and safety of POEM for achalasia. *United Eur Gastroenterol J* 3:325–334. <https://doi.org/10.1177/2050640615581732>
21. Kane ED, Desilets DJ, Wilson D, Leduc M, Budhraj V, Romanelli JR (2018) Treatment of achalasia with per-oral endoscopic myotomy: analysis of 50 consecutive patients. *J Laparoendosc Adv Surg Tech A* 28:514–525. <https://doi.org/10.1089/lap.2017.0588>
22. Pandolfino JE, de Ruigh A, Nicodème F, Xiao Y, Boris L, Kahrilas PJ (2013) Distensibility of the esophagogastric junction assessed with the functional lumen imaging probe (FLIP™) in achalasia patients. *Neurogastroenterol Motil* 25:496–e368. <https://doi.org/10.1111/nmo.12097>
23. Familiari P, Gigante G, Marchese M, Boskoski I, Bove V, Tringali A, Perri V, Onder G, Costamagna G (2014) EndoFLIP system for the intraoperative evaluation of peroral endoscopic myotomy. *United Eur Gastroenterol J* 2:77–83. <https://doi.org/10.1177/2050640614521193>
24. Rieder E, Swanström LL, Perretta S, Lenglinger J, Riegler M, Dunst CM (2013) Intraoperative assessment of esophagogastric junction distensibility during per oral endoscopic myotomy (POEM) for esophageal motility disorders. *Surg Endosc* 27:400–405. <https://doi.org/10.1007/s00464-012-2484-0>
25. Ngamruengphong S, von Rahden BHA, Filser J, Tyberg A, Desai A, Sharaiha RZ, Lambroza A, Kumbhari V, El Zein M, Abdelgelil A, Besharati S, Clarke JO, Stein EM, Kalloo AN, Kahaleh M, Khashab MA (2016) Intraoperative measurement of esophagogastric junction cross-sectional area by impedance planimetry correlates with clinical outcomes of peroral endoscopic myotomy for achalasia: a multicenter study. *Surg Endosc* 30:2886–2894. <https://doi.org/10.1007/s00464-015-4574-2>
26. Teitelbaum EN, Soper NJ, Pandolfino JE, Kahrilas PJ, Hirano I, Boris L, Nicodème F, Lin Z, Hungness ES (2015) Esophagogastric junction distensibility measurements during Heller myotomy and POEM for achalasia predict postoperative symptomatic outcomes. *Surg Endosc* 29:522–528. <https://doi.org/10.1007/s00464-014-3733-1>
27. Su B, Callahan ZM, Novak S, Kuchta K, Ujiki MB (2020) Using impedance planimetry (EndoFLIP) to evaluate myotomy and predict outcomes after surgery for achalasia. *J Gastrointest Surg* 24:964–971. <https://doi.org/10.1007/s11605-020-04513-w>
28. Fujiyoshi Y, Inoue H, Fujiyoshi MRA, Rodriguez de Santiago E, Nishikawa Y, Toshimori A, Tanabe M, Shimamura Y, Sumi K, Ono M, Shiwaku H, Ikeda H, Onimaru M (2022) Learning curve for peroral endoscopic myotomy in therapeutic endoscopy experts and nonexperts: large single-center experience. *Dig Endosc* 35:323–331. <https://doi.org/10.1111/den.14435>
29. Patel KS, Calixte R, Modayil RJ, Friedel D, Brathwaite CE, Stavropoulos SN (2015) The light at the end of the tunnel: a single-operator learning curve analysis for per oral endoscopic myotomy. *Gastrointest Endosc* 81:1181–1187. <https://doi.org/10.1016/j.gie.2014.10.002>
30. Lv H, Zhao N, Zheng Z, Wang T, Yang F, Jiang X, Lin L, Sun C, Wang B (2017) Analysis of the learning curve for peroral endoscopic myotomy for esophageal achalasia: single-center, two-operator experience. *Dig Endosc* 29:299–306. <https://doi.org/10.1111/den.12763>

31. R Core Team (2021) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. <https://www.R-project.org/>
32. Banks-Venegoni AL, Desilets DJ, Romanelli JR, Earle DB (2015) Tension capnopericardium and cardiac arrest as an unexpected adverse event of peroral endoscopic myotomy (with video). *Gastrointest Endosc* 82:1137–1139. <https://doi.org/10.1016/j.gie.2015.07.028>
33. Tyberg A, Seewald S, Sharaiha RZ, Martinez G, Desai AP, Kumta NA, Lambroza A, Sethi A, Reavis KM, DeRoche K, Gaidhane M, Talbot M, Saxena P, Zamarripa F, Barret M, Eleftheriadis N, Balassone V, Inoue H, Kahaleh M (2017) A multicenter international registry of redo per-oral endoscopic myotomy (POEM) after failed POEM. *Gastrointest Endosc* 85:1208–1211. <https://doi.org/10.1016/j.gie.2016.10.015>
34. Chen Y-I, Inoue H, Ujiki M, Draganov PV, Colavita P, Mion F, Romanelli J, Chiu P, Balassone V, Patel L, Abbas A, Yang D, Dunst C, Pioche M, Roman S, Rivory J, Ponchon T, Desilets D, Maselli R, Onimaru M, Nakamura J, Hata Y, Hajiyeva G, Ismail A, Ngamruengphong S, Bukhari M, Chavez YH, Kumbhari V, Repici A, Khashab MA (2018) An international multicenter study evaluating the clinical efficacy and safety of per-oral endoscopic myotomy in octogenarians. *Gastrointest Endosc* 87:956–961. <https://doi.org/10.1016/j.gie.2017.02.007>
35. Li P, Ma B, Gong S, Zhang X, Li W (2020) Gastric per-oral endoscopic myotomy for refractory gastroparesis: a meta-analysis. *J Gastrointest Surg* 25:1108–1116. <https://doi.org/10.1007/s11605-020-04520-x>
36. Grimes KL, Inoue H, Onimaru M, Ikeda H, Tansawet A, Bechara R, Tanaka S (2016) Double-scope per oral endoscopic myotomy (POEM): a prospective randomized controlled trial. *Surg Endosc* 30:1344–1351. <https://doi.org/10.1007/s00464-015-4396-2>
37. Liu Z, Zhang X, Zhang W, Zhang Y, Chen W, Qin W, Hu J, Cai M, Zhou P, Li Q (2018) Comprehensive evaluation of the learning curve for peroral endoscopic myotomy. *Clin Gastroenterol Hepatol* 16:1420–1426.e2. <https://doi.org/10.1016/j.cgh.2017.11.048>

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

## Authors and Affiliations

Matthew F. Mikulski<sup>1,3</sup>  · Timothy J. Morley<sup>1</sup> · Kaitlin P. Debbink<sup>1</sup> · David J. Desilets<sup>2</sup> · John R. Romanelli<sup>1</sup>

✉ Matthew F. Mikulski  
matthew.mikulski@gmail.com

<sup>1</sup> Department of Surgery, University of Massachusetts Chan Medical School - Baystate, Springfield, MA, USA

<sup>2</sup> Department of Gastroenterology, University of Massachusetts Chan Medical School - Baystate, Springfield, MA, USA

<sup>3</sup> Baystate Medical Center, Surgery Education Office, 759 Chestnut Street, Springfield, MA 01199, USA